Franz Faupel received his Ph.D. in physics from the Göttingen University in 1985. He was postdoctoral fellow at the IBM Th. J. Watson Research Center in Yorktown Heights, and got his habilitation from Göttingen University in 1992. Since 1994, he holds the Chair for Multicomponent Materials at Kiel University. Faupel, inter alia, is Chairman of the North German Initiative Nanotechnology and has been serving on several editorial boards including Materials, SN Applied Sciences, Journal of Materials Research, Applied Physics Letters, and Journal of Applied Physics. He was also member of Minerva-Weizmann Committee of the Max Planck Society and Dean of the Faculty of Engineering. He published more than 350 peer reviewed papers on functional nanocomposites, diffusion, glass transition, metallic glasses, plasma deposition, magnetoelectric sensors, metal-polymer interfaces, and other subjects.
A tiny virus makes the world breathless and causes unprecedented activities to develop a protective vaccine. This talk gives a brief background on infection and immune responses and explains how vaccines work. In principle, the vaccine shall anticipate a viral infection to train the immune system to defend the body against a real infection. This can be achieved by different types of vaccines – and all of them involve nanotechnology at some point. It then looks into different vaccination strategies and formulations including own work in the field of mucosal vaccination. Finally, the talk will look into current Corona vaccines in late stage clinical development and gives an insight into results and open questions.
Regina Scherließ (*1979) is a professor for Pharmaceutics and Biopharmaceutics, managing director of the section Pharmacy and chair of the Department of Pharmaceutics at Kiel University, Germany. As such she leads the research unit in Pharmaceutics and is responsible for all teaching in Pharmaceutics and Biopharmaceutics at Kiel University. She is a pharmacist and received her Dr. rer. nat. (doctor of natural sciences) in 2008 for a work on “Formulation of inhalation combination products by co-precipitation”. In 2015 she finished her “habilitation” working on “Mucosal vaccination via the respiratory tract”. During her academic education she had research stays in Denmark, the US, New Zealand and Australia. She also received several young researcher awards including The Pat Burnell New Investigator Award 2010 of the Aerosol Society and is member of the DDL scientific committee (since 2015). She also is member of the board of the research area KiNSIS at Kiel university. Her research interests include disperse systems and nanoparticles, stabilization of biomolecules and particle engineering in spray drying and formulations for mucosal vaccination with a focus on respiratory (nasal and pulmonary) dry powder delivery.
Despite the recent progress in developing potent vaccines for the treatment of COVID-19 still alternative treatment options will be required to combat the pandemic, especially for unvaccinated individuals or individuals who respond poorly to vaccination. One promising approach involves the development of anti-viral therapeutic antibodies. A variety of strategies have been pursued to generate potent neutralizing antibodies, but the effector mechanisms triggered by monoclonal antibodies are complex and different parameters have to be considered to design effective and safe anti-viral antibodies. Selected strategies in clinical development will be discussed.
Matthias Peipp received his PhD at the chair of genetics, Friedrich-Alexander-University, Erlangen-Nuremberg, Germany in 2003. In 2004, he moved to the Christian-Albrechts-University of Kiel (Kiel, Germany), where he studied effector mechanisms mediated by therapeutic antibodies. In 2006, Matthias moved to the Division of Stem Cell Transplantation and Immunotherapy (Kiel, Germany) where he is heading the research division and a research group interested in antibody-based immunotherapy of cancer. In 2015 Matthias was awarded an endowed professorship “Mildred-Scheel-Professorship for experimental antibody-based cancer immunotherapy” funded by the German Cancer Aid. His current work is mainly focused on antibody engineering to improve cancer immunotherapy.
CAMPTON Diagnostics develops in cooperation with the Fraunhofer ISIT a silicon based biochip platform that is applicable for a wide range of immunological and molecular-biological based tests. Therewith it is possible to run a multi-parametric analysis of infectious diseases by detecting the immune response and/or the detection of viral load. For example, this can be used in the diagnosis of the “Severe Acute Respiratory Syndrome Corona-Virus 2 (SARS-CoV-2).
The point of care system of CAMPTON Diagnostics consists essentially of disposable biochip cartridges, reagent containers with stable liquids and a device for processing fully automated assays. After easy sample collection, immunological and molecular-biological assays on gold microelectrodes and electrochemical detection take place.
Overall, the biochip platform combines micro system technology and modern methods of molecular biology resulting in multi-parametric point-of-care tests.
After working as an industrial electronics technician and studying electrical engineering, Lars Blohm developed as a graduate engineer at eBiochip Systems GmbH automated analytical systems with electrical biochips.
In 2009, he started his work as a research scientist at the Fraunhofer Institute of Silicon Technology (ISIT). As project manager of public and industrial projects, he was mainly involved in the development and design of integrated systems for biomedical and energy-efficient MEMS (Micro-Electro-Mechanical Systems).
Since 2019, Lars Blohm is working as co-founder and managing director at CAMPTON Diagnostics. There he is responsible for the development of point of care diagnostic systems based on the electrical biochip technology.
Eric Nebling studied Chemistry in Hamburg (Germany) and did his PhD work at the “Department of Biochemistry” of the University of Hamburg in the biosensor field. He works at Fraunhofer ISIT in the department “Biotechnical Microsystems (BTMS)” as a research scientist since 1999. He was head of this department from 2008 to 2016.
Dr. Eric Nebling´s main field of work are protein based tests on electrical biochips. He was co-responsible for the BMBF-funded project “Silicon chip system for the biochemical analysis technique: Technical platform and system integration (SIBANAT)”. Dr. Nebling was also ISIT´s project leader of the Fraunhofer project “in-vitro-Diagnostic-Platform” (ivD-MAVO and ivD-WISA; internal programs) and the BMBF-funded project “Cellfree Bioproduction”.
Since 2019, Dr. Nebling is working as co-founder and scientific managing director at CAMPTON Diagnostics. There he is responsible for the test development on CAMPTONs point of care diagnostic platform.
The pandemic of Covid-19 changed not only our daily life, but also biopharmaceutical manufacturing worldwide. Richter-Helm BioLogics is a biopharmaceutical company located in Germany with multiple sites. During this talk we will present options for vaccination and treatment of Covid-19 related to microbial manufacturing capacities and challenges resulting from the current situation.
2004 – now: Richter-Helm BioLogics.
Started in Quality Control Bovenau, finally director of Quality Control department in Bovenau, changed to Project management and later to Business development. (Project Management activities were handled in parallel to Quality Control for several years before)
1998 – 2004 Diploma thesis, dissertation (2002) and 2 years post doc at Max-Planck Research Unit “Enzymology of Protein Folding” (Halle / Saale), Director: Gunther Fischer
1993 – 1998 student, course “Biochemistry”; Martin-Luther University Halle /Saale